Lopinavir 192725-17-0

.cp_wz table {border-top: 1px solid #ccc;border-left:1px solid #ccc; } .cp_wz table td{border-right: 1px solid #ccc; border-bottom: 1px solid #ccc; padding: 5px 0px 0px 5px;} .cp_wz table th {border-right: 1px solid #ccc;border-bottom: 1px solid #ccc; padding: 5px 0px 0px 5px;}


Molecular Weight:

628.8 Lopinavir is a potent HIV Protease Inhibitor with Ki of 1.3 pM.






Biological Activity


Lopinavir binds to mutant HIV protease (V82A, V82F and V82T) with Ki of
4.9 pM, 3.7 pM and 3.6 pM, respectively. Lopinavir inhibits 93% of
wild-type HIV protease activity at 0.5 nM. Lopinavir inhibits HIV
protease activity in the absence and presence of 50% HS with EC50 of 17
nM and 102 nM, respectively, in MT4 cells.


Lopinavir is
converted to several metabolites in an NADPH-dependent manner in liver
microsomes with the primary metabolites M-3 and M-4. Lopinavir is a Potent Inhibitor of Rh123 efflux in Caco-2 monolayers
with IC50 of 1.7 mM. Lopinavir exposure (72 hours) in LS 180V cells
reduces the content of intracellular Rh123. Lopinavir induces
P-glycoprotein immunoreactive protein and messenger RNA levels in LS
180V cells.


Lopinavir inhibits subtype C clone C6 with IC50 of 9.4 nM. Lopinavir inhibits CYP3A with IC50 of 7.3 mM in human liver microsomes,
while produces negligible or weak inhibition of human CYP1A2, 2B6, 2C9,
2C19 and 2D6.


Lopinavir (10 mg/kg, orally) results in Cmax of 0.8 μg/mL and oral bioavailability of 25% in rats.

Contact us if you need more details on 192725-17-0. We are ready to answer your questions on packaging, logistics, certification or any other aspects about Lopinavir 192725-17-0、192725-17-0 Lopinavir. If these products fail to match your need, please contact us and we would like to provide relevant information.

Product Categories : Proteases > HIV Protease Inhibitor